ClinicalTrials.gg
Active, not recruitingNCT05622318Updated Nov 6, 2026

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

A Phase 2 interventional study of Cyclophosphamide and Tacrolimus in Graft-versus-host Disease, sponsored by Medical College of Wisconsin. Active, not recruiting at 1 site in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Medical College of Wisconsin · Phase 2, Interventional, and Treatment

How we know

Updated Nov 6, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies testing cyclophosphamide in Graft vs Host Disease — 11 open to participants now, 22 under way, 4 of them phase 3. Cyclophosphamide · Graft vs Host Disease.

Planned enrollment
14th of 47
56 · median 35
Started
2023
with 2 others
Phase 2
22 of 48
6 open now
Primary completion
2028-07
later than 12 of 21 live
Registered
39th of 48
by date

Among the 48 studies testing cyclophosphamide in Graft vs Host Disease, this one is the 14th largest by planned enrollment of the 47 interventional ones that give a count, is one of 3 that started in 2023, is one of 22 in phase 2, reaches primary completion later than 12 of the 21 other live ones, and was the 39th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

11 of the 48 studies testing cyclophosphamide in Graft vs Host Disease are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing cyclophosphamide in Graft vs Host Disease, or all of them as a file.
02

Study summary

This is an open-label phase 2 study designed to explore the efficacy and safety of low-dose PTCy-ruxolitinib GVHD prophylaxis in older adults undergoing allogeneic HCT with a matched sibling or unrelated donor with a peripheral blood stem cell graft.

Read the detailed description

Following reduced intensity conditioning and 8/8-matched peripheral blood transplant on Day 0, all patients will receive a GVHD prophylaxis post-transplant composed of the following: (i) cyclophosphamide administered at 25 mg/kg on Day +3 and +4, (ii) tacrolimus beginning on Day +5 and through Day +180 and administered with a trough target of 5-10 ng/ml through Day +90 and tapered thereafter; (iii) mycophenolate mofetil (MMF) administered at 15 mg/kg thrice daily beginning on Day +5 through Day +35; and (iv) ruxolitinib administered at 5 mg twice daily starting after engraftment (between Days +30 and +60) and continuing through one year post transplant.

03

Conditions studied

  • Graft-versus-host Disease

Browse trials for

Keywords

  • Graft-versus-host disease
  • Ruxolitinib
  • Graft-versus-host disease prophylaxis
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. History of hematologic .
  2. Must be in remission:

    • Acute Leukemia, chronic leukemia, or myelodysplasia/myeloproliferative neoplasm (excluding primary myelofibrosis): No circulating blasts and \<5% blasts in the bone marrow.
    • Hodgkin and non-Hodgkin lymphomas: Chemo-sensitive disease at time of transplant
  3. Patients must have a related or unrelated peripheral blood stem cell donor that is an 8/8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Unrelated donors must be willing to donate peripheral blood stem cells and meet NMDP criteria for donation.
  4. Planned reduced intensity conditioning therapy with fludarabine/melphalan, with total dose of melphalan of 100-140 mg/m\^2 IV or fludarabine/busulfan with total dose of busulfan of 6.4 mg/kg IV.
  5. Performance Scale of 60 or greater.
  6. Male participants must agree to abstinence or to use of barrier during the entire study period.
  7. Female participants of will require a negative pregnancy test and should agree to practice two effective methods of contraception during the entire study period.
  8. Ability to understand a written document, and the willingness to sign it.

Exclusion criteria

Exclusion Criteria:

  1. Prior HCT or Chimeric antigen receptor (CAR) -T cell therapy.
  2. Patients with liver dysfunction evidenced by ≥2x upper limit normal (), except for a history of Gilbert syndrome.
  3. Patients with renal impairment defined by creatinine\<2mg/dL.
  4. Patients with cardiac dysfunction defined by a ≤45%.
  5. Patients with pulmonary dysfunction defined by a (FEV1) or diffusing capacity for carbon monoxide (DLCO) (corrected for ) ≤50% of predicted.
  6. Patients with a chronic or active infection requiring systemic treatment during and after transplant.
  7. Presence of other active malignant disease diagnosed within 12 months, except for adequately treated non-melanoma skin cancer, adequately treated melanoma grade 2 or less, or cervical intraepithelial neoplasia. Active is malignancy receiving treatment.
  8. Pregnant or lactating subjects.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Graft-versus-host disease prophylaxis

    Following reduced intensity conditioning and 8/8-matched peripheral blood transplant on Day 0, all patients will receive a GVHD prophylaxis post-transplant composed of the following: (i) cyclophosphamide administered at 25 mg/kg on Day +3 and +4, (ii) tacrolimus beginning on Day +5 and through Day +180 and administered with a trough target of 5-10 ng/ml through Day +90 and tapered thereafter; (iii) mycophenolate mofetil (MMF) administered at 15 mg/kg thrice daily beginning on Day +5 through Day +35; and (iv) ruxolitinib administered at 5 mg twice daily starting after engraftment (between Days +30 and +60) and continuing through one year post transplant.

    Drug: Cyclophosphamide · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Drug: Ruxolitinib

Interventions

  • 25 mg/kg by IV on Days +3 and +4.

    Also known as: Cytoxan

  • Target level 5-10 ng/mL (If the subject experiences nausea and vomiting that prevents the oral intake of tacrolimus anytime during treatment, tacrolimus is to be given by IV at the appropriate dose that was used to obtain the therapeutic level \[IV:PO ratio = 1:4\]). Administered Days +5 through +90. Taper after Day +90 and discontinue on Day +180.

    Also known as: Astagraf XL, Envarsus XR, Prograf

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    15 mg/kg tablet thrice daily Days +5 through +35 every eight hours.

    Also known as: CellCept

  • 5 mg tablet twice daily after engraftment through Day +365. Taper after Day +365.

    Also known as: INC424, Jakafi

06

What researchers measure

Primary outcomes

  1. The number of subjects who experience GVHD-free survival.

    This measure is defined as being alive without having experienced grade III/IV acute GVHD, or chronic GVHD requiring systemic immune suppression.

    Time frame: One year (365 Days) after hematopoietic cell transplantation (HCT)

Secondary outcomes

  1. The number of subjects with acute GVHD at Day +100.

    The staging and grading of acute GVHD will be done according to Consensus GVHD grading criteria.

    Time frame: Day +100 after HCT

  2. The number of subjects with acute GVHD at Day +180.

    The staging and grading of acute GVHD will be done according to Consensus GVHD grading criteria.

    Time frame: Day +180 after HCT

  3. The number of subjects with chronic GVHD at one year.

    Chronic GVHD will be graded as mild, moderate, or severe according to the NIH consensus criteria.

    Time frame: One year after HCT

  4. The number of subjects with non-relapse mortality at Day +100.

    This is defined as death before day +100 after transplant that was not preceded by recurrent or progressive malignancy.

    Time frame: Day +100 after HCT

  5. The number of subjects with non-relapse mortality at one year.

    This is defined as death before day +100 after transplant that was not preceded by recurrent or progressive malignancy.

    Time frame: One year after HCT

  6. Overall survival at one year.

    This is defined as the number of subjects alive one year after HCT.

    Time frame: One year after HCT

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jul 2028, 58 months after the start.

Of 86 non-industry phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 116. This study's planned 58 months is close to that.

Counting every sponsor, half of 103 studies reached it within 52 months; a quarter within 29 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jul 2026 → Jul 2028 and completion Sep 2026 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2022
First posted
Nov 18, 2022
StartActual
Aug 29, 2023
Primary completionEst.
Jul 8, 2028was Jul 2026
CompletionEst.
Aug 6, 2028was Sep 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Jul 8, 2028
Nov 6, 2026
Study completion
Sep 2026→Aug 6, 2028
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Jul 2026→Jul 8, 2028
    Study completion Sep 2026→Aug 6, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05622318
Responsible party
Sameem M. Abedin, MD (Associate Professor, Medical College of Wisconsin) — Principal investigator
First posted
Nov 18, 2022
Start date
Aug 29, 2023
Primary completion
Jul 8, 2028 (estimated)
Completion
Aug 6, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Sameem Abedin, MD
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Ruxolitinib

Start the discussion